- Home
- BGLC vs TOVX Comparison
BGLC vs TOVX Comparison
Compare BGLC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- TOVX
- Stock Information
- Founded
- BGLC 2017
- TOVX 2001
- Country
- BGLC Malaysia
- TOVX United States
- Employees
- BGLC N/A
- TOVX N/A
- Industry
- BGLC Medical Specialities
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- TOVX Health Care
- Exchange
- BGLC Nasdaq
- TOVX Nasdaq
- Market Cap
- BGLC 5.8M
- TOVX 4.7M
- IPO Year
- BGLC N/A
- TOVX 2006
- Fundamental
- Price
- BGLC $0.25
- TOVX $1.18
- Analyst Decision
- BGLC
- TOVX Strong Buy
- Analyst Count
- BGLC 0
- TOVX 1
- Target Price
- BGLC N/A
- TOVX $6.00
- AVG Volume (30 Days)
- BGLC 1.5M
- TOVX 23.1K
- Earning Date
- BGLC 05-14-2025
- TOVX 05-06-2025
- Dividend Yield
- BGLC N/A
- TOVX N/A
- EPS Growth
- BGLC N/A
- TOVX N/A
- EPS
- BGLC N/A
- TOVX N/A
- Revenue
- BGLC $9,259,858.00
- TOVX N/A
- Revenue This Year
- BGLC N/A
- TOVX N/A
- Revenue Next Year
- BGLC N/A
- TOVX N/A
- P/E Ratio
- BGLC N/A
- TOVX N/A
- Revenue Growth
- BGLC N/A
- TOVX N/A
- 52 Week Low
- BGLC $0.21
- TOVX $1.03
- 52 Week High
- BGLC $1.00
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- BGLC 35.57
- TOVX 44.05
- Support Level
- BGLC $0.23
- TOVX $1.08
- Resistance Level
- BGLC $0.29
- TOVX $1.25
- Average True Range (ATR)
- BGLC 0.02
- TOVX 0.08
- MACD
- BGLC -0.01
- TOVX 0.00
- Stochastic Oscillator
- BGLC 20.22
- TOVX 57.89
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.